



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.
VEN008/01

Serial No.
US
09/991/003

Applicant
Deltagen Proteomics

Filing Date
11-16-01

Grow

rowd 1654

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

EXAMINER

DATE CONSIDERED

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. VEN008/01	Serial No. US 09/991/003
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				Applicant Deltagen Proteomics	
				Filing Date 11-16-01	Group

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

			Andries, K., B. Dewindt, M. De Brabander, R. Stokbroekx, and P. A. Janssen. 1988. In vitro activity of R 61837, a new antirhinovirus compound. <i>Arch Virol.</i> 101:155-67.
			Andries, K., B. Dewindt, J. Snoeks, and R. Willebrords. 1989. Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization. <i>Arch Virol.</i> 106:51-61.
			Badger, J., I. Minor, M. J. Kremer, M. A. Oliveira, T. J. Smith, J. P. Griffith, D. M. Guerin, S. Krishnaswamy, M. Luo, M. G. Rossmann, and et al. 1988. Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. <i>Proc Natl Acad Sci U S A.</i> 85:3304-8
			Badger, J., I. Minor, M. A. Oliveira, T. J. Smith, and M. G. Rossmann. 1989. Structural analysis of antiviral agents that interact with the capsid of human rhinoviruses. <i>Proteins.</i> 6:1-19.
			Baginski, S. G., D. C. Pevear, M. Seipel, S. C. Sun, C. A. Benetas, S. K. Chunduru, C. M. Rice, and M. S. Collett. 2000. Mechanism of action of a pestivirus antiviral compound. <i>Proc Natl Acad Sci U S A.</i> 97:7981-6.
			Blum, J. H., S. L. Dove, A. Hochschild, and J. J. Mekalanos. 2000. Isolation of peptide aptamers that inhibit intracellular processes. <i>Proc Natl Acad Sci U S A.</i> 97:2241-6.
			Brown-Augsburger, P., L. M. Vance, S. K. Malcolm, H. Hsiung, D. P. Smith, and B. A. Heinz. 1999. Evidence that enviroxime targets multiple components of the rhinovirus 14 replication

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Atty. Docket No. VEN008/01	Serial No. US 09/991/003
-------------------------------	--------------------------------

Applicant Deltagen Proteomics

Filing Date 11-16-01	Group
-------------------------	-------

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

		complex. Arch Virol. 144:1569-85.
		Che, Z., N. H. Olson, D. Lelipe, W. M. Lee, A. G. Mosser, R. R. Rueckert, T. S. Baker, and T. J. Smith. 1998. Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes. J Virol. 72:4610-22
		Colombo, R. J., P. L. Callahan, D. M. Lelipe, R. R. Rueckert, and J. E. Tomassini. 1989. Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments. J Virol. 63:36-42.
		Conant, R. M., D. C. Thomas, and V. V. Hamparian. 1970. Properties of rhinovirus plaque mutants. Proc Soc Exp Biol Med. 134:677-82.
		DeLong, D. C., and S. E. Reed. 1980. Inhibition of rhinovirus replication in organ culture by a potential antiviral drug. J Infect Dis. 141:87-91.
		Dragovich, P. S., T. J. Prins, R. Zhou, S. E. Webber, J. T. Marakovits, S. A. Fuhrman, A. K. Patick, D. A. Matthews, C. A. Lee, C. E. Ford, B. J. Burke, P. A. Rejto, T. F. Hendrickson, T. Tuntland, E. L. Brown, J. W. Meador, 3rd, R. A. Ferre, J. E. Harr, M. B. Kosa, and S. T. Worland. 1999. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem. 42:1213-24.
		Dragovich, P. S., S. E. Webber, R. E. Babine, S. A. Fuhrman, A. K. Patick, D. A. Matthews, C. A. Lee, S. H. Reich, T. J. Prins, J. T. Marakovits, E. S. Littlefield, R. Zhou, J. Tikhe, C. E. Ford, M. B. Wallace, J. W. Meador, 3rd, R. A. Ferre, E. L. Brown, S. L. Binford, J. E. Harr, D. M. DeLisle, and S. T. Worland. 1998. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J Med Chem. 41:2806-18.
		Evans, M. R., J. H. Hughes, C. Gercel, and V. V. Hamparian. 1980. Isolation and genetic analysis of temperature-sensitive mutants of rhinovirus type 2. Intervirology. 13:299-306.
		Garozzo, A., C. C. Cutri, A. Castro, G. Tempera, F. Guerrera, M. C. Sarva, and E. Geremia. 2000. Anti-rhinovirus activity of 3-methylthio-5-aryl-4- isothiazolecarbonitrile derivatives. Antiviral Res. 45:199-210.
		Gauntt, C. J. 1980. Fragility of the rhinovirus type 14 genome to incubation at 60 degrees. Intervirology. 13:7-15.
		Gauntt, C. J. 1979. Rhinovirus type 14 persistence in HeLa cells studied by use of guanidine. J Med Virol. 4:115-24.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. VEN008/01	Serial No. US 09/991/003
INFORMATION DISCLOSURE STATEMENT			Applicant Deltagen Proteomics	
(Use several sheets if necessary)			Filing Date 11-16-01	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

			Gercel, C., K. B. Mahan, and V. V. Hamparian. 1985. Preliminary characterization of a persistent infection of HeLa cells with human rhinovirus type 2. <i>J Gen Virol.</i> 66 :131-9.
			Gern, J. E., E. C. Dick, W. M. Lee, S. Murray, K. Meyer, Z. T. Handzel, and W. W. Busse. 1996. Rhinovirus enters but does not replicate inside monocytes and airway macrophages. <i>J Immunol.</i> 156 :621-7.
			Geyer, C. R., and R. Brent. 2000. Selection of genetic agents from random peptide aptamer expression libraries. <i>Methods Enzymol.</i> 328 :171-208.
			Geyer, C. R., A. Colman-Lerner, and R. Brent. 1999. "Mutagenesis" by peptide aptamers identifies genetic network members and pathway connections. <i>Proc Natl Acad Sci U S A.</i> 96 :8567-72.
			Heinz, B. A., R. R. Rueckert, D. A. Shepard, F. J. Dutko, M. A. McKinlay, M. Fancher, M. G. Rossmann, J. Badger, and T. J. Smith. 1989. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. <i>J Virol.</i> 63 :2476-85.
			Hendley, J. O., R. D. Abbott, P. P. Beasley, and J. M. Gwaltney. 1994. Effect of inhalation of hot humidified air on experimental rhinovirus infection. <i>Jama.</i> 271 :1112-3.
			Hughes, J. H., M. Mitchell, and V. V. Hamparian. 1979. Rhinoviruses: kinetics of ultraviolet inactivation and effects of UV and heat on immunogenicity. <i>Arch Virol.</i> 61 :313-9.
			Hughes, J. H., D. C. Thomas, V. V. Hamparian, and H. G. Cramblett. 1973. Acid lability of rhinovirus type 14: effect of pH, time, and temperature. <i>Proc Soc Exp Biol Med.</i> 144 :555-60.
			Killington, R. A., E. J. Stott, and D. Lee. 1977. The effect of temperature on the synthesis of rhinovirus type 2 RNA. <i>J Gen Virol.</i> 36 :403-11.
			Lee, W. M., W. Wang, and R. R. Rueckert. 1995. Complete sequence of the RNA genome of human rhinovirus 16, a clinically useful common cold virus belonging to the ICAM-1 receptor group. <i>Virus Genes.</i> 9 :177-81
			Lonberg-Holm, K., and B. D. Korant. 1972. Early interaction of rhinoviruses with host cells. <i>J Virol.</i> 9 :29-40.
			Lonberg-Holm, K., and J. Noble-Harvey. 1973. Comparison of in vitro and cell-mediated alteration of a human Rhinovirus and its inhibition by sodium dodecyl sulfate. <i>J Virol.</i> 12 :819-26.
			Lorens, J. B., M. K. Bennett, D. M. Pearsall, W. R. Thronset, A. B. Rossi, R. J. Armstrong, B. P. Fox, E. H. Chan, Y. Luo, E. Masuda, D. A. Ferrick, D. C. Anderson, D. G. Payan, and G. P. Nolan. 2000. Retroviral delivery of peptide modulators of cellular functions. <i>Mol Ther.</i> 1 :438-47.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. VEN008/01	Serial No. US 09/991/003
INFORMATION DISCLOSURE STATEMENT			Applicant Deltagen Proteomics	
(Use several sheets if necessary)			Filing Date 11-16-01	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

			Matthews, D. A., P. S. Dragovich, S. E. Webber, S. A. Fuhrman, A. K. Patick, L. S. Zalman, T. F. Hendrickson, R. A. Love, T. J. Prins, J. T. Marakovits, R. Zhou, J. Tikhe, C. E. Ford, J. W. Meador, R. A. Ferre, E. L. Brown, S. L. Binford, M. A. Brothers, D. M. DeLisle, and S. T. Worland. 1999. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. <i>Proc Natl Acad Sci U S A</i> . 96:11000-7.
			Miller, A. D., and G. J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. <i>Biotechniques</i> . 7:980-2, 984-6, 989-90.
			Mosser, A. G., D. A. Shepard, and R. R. Rueckert. 1994. Use of drug-resistance mutants to identify functional regions in picornavirus capsid proteins. <i>Arch Virol Suppl</i> . 9:111-9.
			Neubauer, C., L. Frasel, E. Kuechler, and D. Blaas. 1987. Mechanism of entry of human rhinovirus 2 into HeLa cells. <i>Virology</i> . 158:255-8.
			Noble-Harvey, J., and K. Lonberg-Holm. 1974. Sequential steps in attachment of human rhinovirus type 2 to HeLa cells. <i>J Gen Virol</i> . 25:83-91.
			Norman, T. C., D. L. Smith, P. K. Sorger, B. L. Drees, S. M. O'Rourke, T. R. Hughes, C. J. Roberts, S. H. Friend, S. Fields, and A. W. Murray. 1999. Genetic selection of peptide inhibitors of biological pathways. <i>Science</i> . 285:591-5.
			Orr, D. C., A. C. Long, J. Kay, B. M. Dunn, and J. M. Cameron. 1989. Hydrolysis of a series of synthetic peptide substrates by the human rhinovirus 14 3C proteinase, cloned and expressed in <i>Escherichia coli</i> . <i>J Gen Virol</i> . 70:2931-42.
			Palmenberg, A. 1987. Antipeptide antibodies. A vaccine for the common cold? <i>Nature</i> . 329:668-9.
			Patick, A. K., S. L. Binford, M. A. Brothers, R. L. Jackson, C. E. Ford, M. D. Diem, F. Maldonado, P. S. Dragovich, R. Zhou, T. J. Prins, S. A. Fuhrman, J. W. Meador, L. S. Zalman, D. A. Matthews, and S. T. Worland. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. <i>Antimicrob Agents Chemother</i> . 43:2444-50.
			Resnick, D. A., A. D. Smith, A. Zhang, S. C. Geisler, E. Arnold, and G. F. Arnold. 1994. Libraries of human rhinovirus-based HIV vaccines generated using random systematic mutagenesis. <i>AIDS Res Hum Retroviruses</i> . 10:S47-52
			Smith, A. D., D. A. Resnick, A. Zhang, S. C. Geisler, E. Arnold, and G. F. Arnold. 1994. Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences. <i>J Virol</i> . 68:575-9.
			Smith, T. J., N. H. Olson, R. H. Cheng, H. Liu, E. S. Chase, W. M. Lee, D. M. Leippe, A. G. Mosser, R. R. Rueckert, and T. S. Baker. 1993. Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody. <i>J Virol</i> . 67:1148-58.
			Stott, E. J., and G. F. Heath. 1970. Factors affecting the growth of Rhinovirus 2 in suspension cultures of L132 cells. <i>J Gen Virol</i> . 6:15-24.
			Wang, W., W. M. Lee, A. G. Mosser, and R. R. Rueckert. 1998. WIN 52035-dependent human rhinovirus 16: assembly deficiency caused by mutations near the canyon surface. <i>J Virol</i> . 72:1210-8.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. VEN008/ 01	Serial No. US 09/991/003
 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Applicant Deltagen Proteomics	
			Filing Date 11-16-01	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
		Xing, L., K. Tjarnlund, B. Lindqvist, G. G. Kaplan, D. Felgelson, R. H. Cheng, and J. M. Casasnovas. 2000. Distinct cellular receptor interactions in poliovirus and rhinoviruses. <i>Embo J.</i> 19:1207-16.		
		Yin, F. H., and E. Knight. 1972. In vivo and in vitro synthesis of human rhinovirus type 2 ribonucleic acid. <i>J Virol.</i> 10:93-8.		
		Yin, F. H., and N. B. Lomax. 1983. Host range mutants of human rhinovirus in which nonstructural proteins are altered. <i>J Virol.</i> 48:410-8.		
		Zalman, L. S., M. A. Brothers, P. S. Dragovich, R. Zhou, T. J. Prins, S. T. Worland, and A. K. Patick. 2000. Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor. <i>Antimicrob Agents Chemother.</i> 44:1236-41		
		Heinz, B. A., and L. M. Vance. 1995. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. <i>J Virol.</i> 69:4189-97.		
		Heinz, B. A., and L. M. Vance. 1996. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. <i>J Virol.</i> 70:4854-7.		
		Lee, M. S., B. Cohen, J. Hand, and D. J. Nokes. 1999. A simplified and standardized neutralization enzyme immunoassay for the quantification of measles neutralizing antibody. <i>J Virol Methods.</i> 78:209-17.		
		Reagan, K. J., M. L. McGeady, and R. L. Crowell. 1981. Persistence of human rhinovirus infectivity under diverse environmental conditions. <i>Appl Environ Microbiol.</i> 41:618-27.		
		Roninson, I. B., A. V. Gudkov, T. A. Holzmayer, D. J. Kirschling, A. R. Kazarov, C. R. Zelnick, I. A. Mazo, S. Axenovich, and R. Thimmapaya. 1995. Genetic suppressor elements: new tools for molecular oncology-- thirteenth Cornelius P. Rhoads Memorial Award Lecture. <i>Cancer Res.</i> 55:4023-8.		
		Sandrock, T. M., B. Risley, B. T. Richards, M. A. Poritz, H. A. Austin, S. Yoo, M. K. Kim, B. Roth, K. Repetny, F. Hsu, M. Stump, D. H. Teng, and A. Kamb. 2001. Exogenous peptide and protein expression levels using retroviral vectors in human cells. <i>Mol Ther.</i> 4:398-406.		

not available

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	